The 14-3-3η Biomarker Platform for Diagnosis and Prognostic Monitoring of Patients with Rheumatoid Arthritis
Introduction. There are several gaps in the clinical evaluation and management of patients with rheumatoid arthritis (RA) that could be addressed through the development of new biomarkers. These include diagnostic biomarkers for primary care physicians that facilitate early referral to a rheumatolog...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Publishing House "Kyrylytsya"
2024-03-01
|
| Series: | Львівський клінічний вісник |
| Subjects: | |
| Online Access: | https://lcb-journal.com/index.php/journal/article/view/81 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849701426669813760 |
|---|---|
| author | W. Maksymowych |
| author_facet | W. Maksymowych |
| author_sort | W. Maksymowych |
| collection | DOAJ |
| description | Introduction. There are several gaps in the clinical evaluation and management of patients with rheumatoid arthritis (RA) that could be addressed through the development of new biomarkers. These include diagnostic biomarkers for primary care physicians that facilitate early referral to a rheumatologist and modifiable biomarkers that guide prognostic assessment and inform rheumatologists on the need for more intensive treatment.
The aim of the study.To review the literature regarding the 14-3-3η biomarker platform for diagnosis and prognostic monitoring of patients with rheumatoid arthritis.
Materials and methods. Content analysis, the method of systematic and comparative analysis, the bibliosemantic method of studying the current scientific research on 14-3-3η biomarker platform for diagnosis and prognostic monitoring of patients with RA were used.
Results. The 14-3-3ηprotein is a new biomarker that is physiologically an intracellular chaperone but is detected extracellularly in joint fluid and peripheral blood specifically in patients with RA. Levels of this protein correlated with expression of metalloproteinases capable of degrading joint cartilage and with factors that enhance activation of osteoclasts. The mechanism of secretion into extracellular fluid may involve necrosis of synovial cells induced by tumor necrosis factor alpha (TNF-a).It enhances diagnostic accuracy of rheumatoid factor and anti-cyclic citrullinated peptide antibodies for detection of RA and is associated with more severe disease but correlates poorly with acute phase reactants such as C-reactive protein. Levels are reduced by several treatments, notably agents that target interleukin-6 and TNF-a. Prospective studies demonstrate that serial measures of 14-3-3η reflect prognostic risk for progression of joint damage on radiography, especially when used in combination with acute phase reactants. The extracellular appearance of 14-3-3η may induce antibodies to this protein which may themselves have diagnostic utility.
Conclusions. The14-3-3η protein is selectively found in the joints and peripheral blood of patients with rheumatoid arthritis. It has properties of an inflammatory mediator in culture experiments involving monocytic and innate immune cells and levels in rheumatoid arthritis patients correlate with those of metalloproteinases associated with cartilage degradation. Longitudinal studies and serial assessment of 14-3-3η demonstrate that higher levels increase the risk for future joint damage in rheumatoid arthritis. These data should be replicated in additional cohorts. |
| format | Article |
| id | doaj-art-1c6420023fe04d67a9cecfd0352743de |
| institution | DOAJ |
| issn | 2306-4269 2520-2898 |
| language | English |
| publishDate | 2024-03-01 |
| publisher | Publishing House "Kyrylytsya" |
| record_format | Article |
| series | Львівський клінічний вісник |
| spelling | doaj-art-1c6420023fe04d67a9cecfd0352743de2025-08-20T03:17:57ZengPublishing House "Kyrylytsya"Львівський клінічний вісник2306-42692520-28982024-03-011 (45)647210.25040/lkv2024.01.06481The 14-3-3η Biomarker Platform for Diagnosis and Prognostic Monitoring of Patients with Rheumatoid ArthritisW. Maksymowych0Division of Rheumatology, University of Alberta, Edmonton, CanadaIntroduction. There are several gaps in the clinical evaluation and management of patients with rheumatoid arthritis (RA) that could be addressed through the development of new biomarkers. These include diagnostic biomarkers for primary care physicians that facilitate early referral to a rheumatologist and modifiable biomarkers that guide prognostic assessment and inform rheumatologists on the need for more intensive treatment. The aim of the study.To review the literature regarding the 14-3-3η biomarker platform for diagnosis and prognostic monitoring of patients with rheumatoid arthritis. Materials and methods. Content analysis, the method of systematic and comparative analysis, the bibliosemantic method of studying the current scientific research on 14-3-3η biomarker platform for diagnosis and prognostic monitoring of patients with RA were used. Results. The 14-3-3ηprotein is a new biomarker that is physiologically an intracellular chaperone but is detected extracellularly in joint fluid and peripheral blood specifically in patients with RA. Levels of this protein correlated with expression of metalloproteinases capable of degrading joint cartilage and with factors that enhance activation of osteoclasts. The mechanism of secretion into extracellular fluid may involve necrosis of synovial cells induced by tumor necrosis factor alpha (TNF-a).It enhances diagnostic accuracy of rheumatoid factor and anti-cyclic citrullinated peptide antibodies for detection of RA and is associated with more severe disease but correlates poorly with acute phase reactants such as C-reactive protein. Levels are reduced by several treatments, notably agents that target interleukin-6 and TNF-a. Prospective studies demonstrate that serial measures of 14-3-3η reflect prognostic risk for progression of joint damage on radiography, especially when used in combination with acute phase reactants. The extracellular appearance of 14-3-3η may induce antibodies to this protein which may themselves have diagnostic utility. Conclusions. The14-3-3η protein is selectively found in the joints and peripheral blood of patients with rheumatoid arthritis. It has properties of an inflammatory mediator in culture experiments involving monocytic and innate immune cells and levels in rheumatoid arthritis patients correlate with those of metalloproteinases associated with cartilage degradation. Longitudinal studies and serial assessment of 14-3-3η demonstrate that higher levels increase the risk for future joint damage in rheumatoid arthritis. These data should be replicated in additional cohorts.https://lcb-journal.com/index.php/journal/article/view/81rheumatoid arthritis, diagnosis, prognosis, 14-3-3η, biomarker |
| spellingShingle | W. Maksymowych The 14-3-3η Biomarker Platform for Diagnosis and Prognostic Monitoring of Patients with Rheumatoid Arthritis Львівський клінічний вісник rheumatoid arthritis, diagnosis, prognosis, 14-3-3η, biomarker |
| title | The 14-3-3η Biomarker Platform for Diagnosis and Prognostic Monitoring of Patients with Rheumatoid Arthritis |
| title_full | The 14-3-3η Biomarker Platform for Diagnosis and Prognostic Monitoring of Patients with Rheumatoid Arthritis |
| title_fullStr | The 14-3-3η Biomarker Platform for Diagnosis and Prognostic Monitoring of Patients with Rheumatoid Arthritis |
| title_full_unstemmed | The 14-3-3η Biomarker Platform for Diagnosis and Prognostic Monitoring of Patients with Rheumatoid Arthritis |
| title_short | The 14-3-3η Biomarker Platform for Diagnosis and Prognostic Monitoring of Patients with Rheumatoid Arthritis |
| title_sort | 14 3 3η biomarker platform for diagnosis and prognostic monitoring of patients with rheumatoid arthritis |
| topic | rheumatoid arthritis, diagnosis, prognosis, 14-3-3η, biomarker |
| url | https://lcb-journal.com/index.php/journal/article/view/81 |
| work_keys_str_mv | AT wmaksymowych the1433ēbiomarkerplatformfordiagnosisandprognosticmonitoringofpatientswithrheumatoidarthritis AT wmaksymowych 1433ēbiomarkerplatformfordiagnosisandprognosticmonitoringofpatientswithrheumatoidarthritis |